Logotype for Vistin Pharma

Vistin Pharma (VISTN) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Vistin Pharma

Q3 2026 earnings summary

29 Oct, 2026

Executive summary

  • Q3 revenue was NOK 108.4m, broadly unchanged YoY, while EBITDA was NOK 18.852m vs NOK 28.047m; record sales volume rose 13% to 1,610 MT.

  • Jan–Sep sales volume increased 10% to 4,710 MT, while revenue declined 6% to NOK 320.808m and EBITDA to NOK 68.234m; currency-neutral revenue was approximately flat.

  • A four-week Q4 maintenance stop to replace the main distillation vessel will idle both production lines and constrain quarterly production and sales.

Financial highlights

  • Q3 revenue was NOK 108.4m vs NOK 108.8m YoY; FX-neutral revenue increased ~7%, offset by lower average selling prices and stronger NOK.

  • Q3 EBITDA was NOK 18.852m vs NOK 28.047m; EBIT was NOK 12.972m vs NOK 21.344m, and net profit was NOK 10.946m vs NOK 18.525m.

  • Jan–Sep revenue was NOK 320.808m vs NOK 341.546m; EBITDA was NOK 68.234m vs NOK 88.536m, and net profit was NOK 46.574m vs NOK 58.694m.

  • Q3 operating expenses were NOK 89.5m vs NOK 80.8m, mainly reflecting higher volume and raw-material costs; salary costs benefited from no bonus accrual vs NOK 2.5m in Q3 2025.

  • Q3 net finance was positive NOK 0.1m vs NOK 2.4m; Jan–Sep net finance was positive NOK 8.2m vs NOK 3.7m.

Outlook and guidance

  • Q4 gross-margin recovery is expected as most higher-priced raw materials purchased during the Hormuz disruption have been consumed.

  • 2027 sales volume is expected to increase from Q3 levels; management expects process fine-tuning to support the 7,000 MT target without significant CapEx.

  • Existing capacity is up to ~7,000 MT annually; further capacity and unit-cost improvements are under review.

  • Metformin demand is forecast to grow 4%–6% annually; growth, productivity and sustainability require additional CapEx, while volume growth and safety-stock plans may raise working-capital needs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Vistin Pharma